Bluejay Therapeutics
Dmitry Koltun has an extensive work experience in the field of medicinal chemistry. Dmitry is currently working at BlueJay Therapeutics as a Senior Director of Medicinal Chemistry since May 2022. Prior to this, they worked at Gilead Sciences where they held several roles including Principal Scientist I from January 2019 to May 2022, Senior Research Scientist II from January 2017 to January 2019, and Senior Research Scientist I from April 2009 to January 2017. Before joining Gilead Sciences, Dmitry worked at CV Therapeutics as a Senior Research Scientist from January 2002 to April 2009. Dmitry also worked at MediChem Life Sciences as a Research Scientist from August 1999 to January 2002.
Dmitry Koltun completed their education in the field of chemistry. Dmitry obtained a Bachelor of Science degree in Chemistry from the Mendeleyev University of Chemical Technology of Russia from the year 1990 to 1994. Subsequently, they pursued further studies and earned a Ph.D. in Organic Chemistry from the University of Minnesota during the period from 1994 to 1999.
This person is not in any teams
Bluejay Therapeutics
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.